275 SHORELINE DRIVE, SUITE 500, REDWOOD CITY, CA
Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism
Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update
Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting
Provides Update on its Congenital Hyperinsulinism Program Following FDA Meeting
Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update
A Late - Stage Rare Disease Company Treating Hyperinsulinism Presentation
2026 Annual Meeting Results; Directors Elected at Rezolute, Inc.
Reg. FD
Q3
Q2
Q1
FY 2025
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Schedule 13G - Ownership Report
Amended Schedule 13G - Ownership Report
Correspondence
Submission Upload